The inhibition of myeloperoxidase by ceruloplasmin can be reversed by anti-myeloperoxidase antibodies  by Griffin, Siân V. et al.
Kidney International, Vol. 55 (1999), pp. 917–925
The inhibition of myeloperoxidase by ceruloplasmin can
be reversed by anti-myeloperoxidase antibodies
SIAˆN V. GRIFFIN, PHILIP T. CHAPMAN, ELIAS A. LIANOS, and C. MARTIN LOCKWOOD
Cambridge University Department of Medicine, Addenbrooke’s Hospital, Cambridge, England, United Kingdom,
and the University Hospital of Heraklion, Crete, Greece
Inhibition of myeloperoxidase by ceruloplasmin can be re- which acts as a potent bactericidal agent by catalyzing
versed by anti-myeloperoxidase antibodies. the production of hypochlorous acid, and hence reactive
Background. The purpose of this study was to characterize oxygen species, from hydrogen peroxide and chloridethe recently reported inhibition of myeloperoxidase (MPO) by
ions [1]. The extracellular release of MPO has been re-ceruloplasmin and to determine whether this may be disturbed
ported to occur in a number of inflammatory diseasesin the presence of anti-MPO antibodies.
Methods. Specificity of the binding between ceruloplasmin in which the potential of MPO to cause tissue injury is
and MPO was confirmed by Western blotting and enzyme- supported by histological evidence [2]. In the context of
linked immunosorbent assay (ELISA), and the enzymatic ac- the pathogenesis of renal disease, a number of studiestivity of MPO was measured in the presence of ceruloplasmin,
have shown that MPO may play a role on a charge basis.affinity-purified anti-MPO antibodies, or both. The affinity of
the binding between MPO and ceruloplasmin and MPO and MPO, being highly cationic, localizes to anionic sites on
the anti-MPO antibodies was measured using a biosensor, with the glomerular basement membrane when infused into
the results confirmed by chaotrope ELISA. the renal artery of rats [3]. After an infusion of hydrogen
Results. Affinity-purified anti-MPO antibodies from pa-
peroxide and chloride ions, over several days endothelialtients with microscopic polyangiitis and florid renal vasculitis
cell swelling and lysis develops along with significantinhibited the binding between ceruloplasmin and MPO to a
maximum of 72.9 6 12.8%, whereas those from patients with proteinuria. In human disease, MPO has been identified
Wegener’s granulomatosis and only minimal renal involvement bound to the glomerular basement membrane in rapidly
inhibited the binding to a maximum of only 36.8 6 10.9% progressive glomerulonephritis [4]. Additionally, hypo-(P , 0.001), with comparable reversal of the ceruloplasmin-
chlorite modification of proteins, a unique hallmark ofmediated inhibition of MPO activity. Measurement of the af-
MPO activity, has been identified in both sclerotic andfinity of the interactions demonstrated that binding between
MPO and the anti-MPO antibodies is stronger than that be- inflammatory renal lesions [5].
tween MPO and ceruloplasmin (1.61 3 107 to 1.33 3 108 vs. Anti-myeloperoxidase antibodies are associated with
7.46 3 106 m21), indicating that binding to the autoantibody
the development of a necrotizing vasculitis, either local-would be favored in vivo.
ized entirely to the kidney or in the context of systemicConclusions. This study confirms a role for ceruloplasmin
as a physiological inhibitor of MPO, and demonstrates how vasculitis [6]. These antibodies stimulate degranulation
the inhibition may be disrupted in the presence of anti-MPO of primed neutrophils, with release of granule enzymes.
antibodies. Because a majority (16 of 21) of the antibodies did Perfusion of neutrophil lysosomal extract and hydrogennot themselves inhibit MPO activity, their interference with the
peroxide into the kidney of Brown Norway rats pre-inhibition mediated by ceruloplasmin may be brought about by
viously immunized with MPO results in the developmentsteric hindrance consequent upon the binding of the antibody
to a dominant epitope at or near the active site. of a proliferative necrotizing crescentic glomerulone-
phritis resembling the human disease, suggesting that
the development of anti-MPO–associated glomerulone-
Myeloperoxidase (MPO) is a glycosylated heme- phritis in this model is dependent on the release of neu-
enzyme, found in the primary granules of neutrophils, trophil enzymes in the presence of an anti-MPO immune
response [7]. In contrast to the neutrophil proteinases,
the mechanism of regulation of MPO activity is poorlyKey words: ANCA, reactive oxygen species, bactericide, vasculitis,
crescentic glomerulonephritis, antioxidant. characterized. In this article, experiments are reported
that demonstrate the binding of ceruloplasmin to MPOReceived for publication April 28, 1998
with subsequent inhibition of enzymatic activity, ex-and in revised form September 10, 1998
Accepted for publication September 24, 1998 tending the recent finding of Segelmark et al [8]. This
action of ceruloplasmin as a possible antioxidant, provid- 1999 by the International Society of Nephrology
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ing protection against MPO-generated free-radical dam- cording to the criteria of the Chapel Hill consensus con-
ference [13]. None of the patients had autoantibodiesage, was first described in 1982 [9]. This study showed
that the methionine residues of a1 antitrypsin (a1AT) directed against the two other major antineutrophil cyto-
plasmic antibody antigens, proteinase 3 and bactericidal/could be oxidatively modified by MPO with a subsequent
reduction in the ability of a1AT to inactivate serine pro- permeability-increasing protein. All sera from the pa-
tients with microscopic polyangiitis were obtained at ini-teases; this reduction was reversed in the presence of
ceruloplasmin. We have also studied the effect on this tial presentation. That from the patient with Churg
Strauss syndrome and two of the six samples from pa-inhibition of anti-MPO antibodies, affinity purified from
patients with microscopic polyangiitis and florid renal tients with Wegener’s granulomatosis were obtained at
relapse. There was no significant difference in the anti-vasculitis or Wegener’s granulomatosis and minimal re-
nal involvement. MPO titer between the patients in each group (micro-
scopic polyangiitis, 80 6 27%; Wegener’s granulomato-
sis, 60 6 25%; Churg Strauss syndrome, 95%; normal
METHODS
range less than 16% of positive control). Comparable
Source of myeloperoxidase binding was seen to native and recombinant MPO in all
but one patient (patient 10). The patients with micro-Native MPO was prepared as previously described
[10]. Briefly, a neutrophil granule preparation was pro- scopic polyangiitis tended to have more florid disease
with life-threatening organ involvement, whereas thoseduced from fresh, white blood cells (buffy coats), col-
lected from normal blood donors, and MPO was purified patients with Wegener’s granulomatosis tended to have
more indolent disease; renal involvement was seen inby strong cation exchange chromatography using a
MonoS HR10/10 prepacked column (Pharmacia, St. Al- only two of these patients and was mild. The clinical
features and laboratory findings in the 21 patients areban’s, UK). The absence of contaminating proteins was
verified by polyacrylamide gel electrophoresis (PAGE), outlined in Table 1.
and the MPO was stored at 48C prior to use.
Affinity purification of anti-myeloperoxidaseRecombinant MPO (rMPO) was also used for the
antibodiesaffinity purification of anti-MPO antibodies and was a
gift from Dr. N. Moguilevsky (Free University of Brus- The sera were passed over the MPO columns, and the
eluted fractions were lyophilized, resuspended in water,sels, Belgium). The recombinant protein is produced as a
monomeric MPO precusor of 84 kDa in Chinese hamster and dialyzed extensively against PBS prior to separation
of the proteins by PAGE. In addition to the expectedovary cells [11]. Despite structural differences, rMPO is
enzymatically active and recognized as an antigen by up band of molecular weight of 150 kDa, corresponding to
anti-MPO IgG, a further protein of the approximateto 95% of anti-MPO positive sera [12].
molecular weight of 130 kDa was eluted. The eluted
Preparation of myeloperoxidase columns fractions were then passed over a protein G column
(Pharmacia) to separate the IgG from the unidentifiedColumns for affinity purification of anti-MPO antibod-
ies were made by coupling either native or recombinant protein, the eluted and unbound fractions concentrated
as mentioned earlier here, and the proteins again visual-MPO at a density of 0.5 mg/ml to cyanogen bromide-
activated sepharose beads as per the manufacturer’s in- ized by PAGE. The unknown protein was identified as
ceruloplasmin by N-terminal sequencing (by Miss C.structions (Pharmacia). This coupling density has been
shown in previous experiments to be the optimum for Sparks and Dr. R. Harrison, MRC Laboratory of Molec-
ular Biology, Cambridge, UK). Both native and recombi-plasma clearance of the antibodies. The coupled beads
were packed in a Pharmacia Biotech XK 16/20 column, nant MPO columns were used to ensure that the copuri-
fication of ceruloplasmin was not an artifact due toequilibrated with phosphate-buffered saline (PBS), pH
7.4, containing 0.25 m NaCl and stored at 48C until used. binding to a contaminant in the native preparation. The
protein concentrations of the anti-MPO antibody prepa-
Patient characteristics rations were measured by the Bradford assay [14] to
enable standardization between samples in subsequentSera were obtained from patients with active vasculitis
and positivity for anti-MPO antibodies, as determined assays.
by indirect immunofluorescence on ethanol-fixed neu-
Western blot of ceruloplasmin bindingtrophils and antigen-specific enzyme-linked immunosor-
to myeloperoxidasebent assay (ELISA). The patients had a clinical and
histologic diagnosis of microscopic polyangiitis (N 5 14, Native MPO was run on a 12% polyacrylamide gel
and was immunoblotted to nitrocellulose paper. Staining9 females, mean age 67 years), Wegener’s granulomatosis
(N 5 6, 3 females, mean age 63 years), or Churg Strauss with ponceau S confirmed an effective protein transfer,
and blocking was carried out with 2% dried, skimmedsyndrome (N 5 1, female, age 60 years), classified ac-
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Table 1. Clinical features and laboratory findings
Anti-MPO titer (%)
Reversal of CP Significance (P value)(NR , 16)
Inhibition of CP mediated KA of binding of KA MPO-antibody
Post-affinity Organ binding to MPO inhibition of to MPO 6sd binding versus KA
Patient Sex Age Diagnosis Serum purification involvement in ELISA (%) MPO activity % (X 107 m21) of MPO binding to CP
1 F 70 MP 104 93 K,L 70 70 ND
2 F 28 MP 86 83 K 78 78 ND
3 F 60 CSS 95 93 L,S,N 67 70 2.3561.53 NS
4 M 70 MP 100 105 K 89 — ND
5 M 68 MP 62 88 K,L 73 71 3.7464.78 NS
6 F 75 MP 30 84 K 58 60 ND
7 F 70 MP 101 81 K,L 71 88 ND
8 F 70 MP 97 96 K,L 77 76 6.4362.88 0.01
9 F 70 MP 75 98 K,L 68 — ND
10 M 72 MP 93 95 K,L,S 71 85 ND
11 F 62 MP 86 86 K,L,S 64 69 2.9561.77 NS
12 F 71 MP 107 95 K,L 77 86 13.30610.10 0.02
13 M 75 MP 99 100 K,L 82 97 6.6263.49 0.02
14 F 60 MP 30 90 K,S 68 — ND
15 M 74 MP 37 102 K 69 85 8.6863.57 0.0005
16 F 70 WG 85 124 ENT,J,E 32 27 1.6160.90 0.05
17 M 67 WG 32 75 ENT,L 20 28 ND
18 F 72 WG 29 95 ENT,L,S 35 16 ND
19 F 64 WG 62 111 ENT,L,E 47 — ND
20 M 57 WG 87 86 ENT,K 44 — ND
21 M 48 WG 66 99 K,J 16 0 2.0960.52 0.05
Abbreviations are: CP, ceruloplasmin; KA, apparent affinity constant; CSS, Churg Strauss syndrome; WG, Wegener’s granulomatosis; MP, microscopic polyangiitis;
K, kidney; L, lung; S, skin; N, neurological; ENT, ear, nose and throat; J, joints, E, eyes.
milk (Marvel) in Tris-buffered saline with 0.1% Tween20 coated plate prior to ceruloplasmin. Binding was de-
tected by the addition of a goat polyclonal anticerulo-(TBSTM) for one hour at room temperature. The nitro-
cellulose was then cut into six strips, and three of these plasmin antibody and subsequently an alkaline phospha-
tase-conjugated monoclonal antisheep IgG (Sigma, Gil-were incubated overnight at 48C with ceruloplasmin
(CalBiochem biochemicals, Nottingham, UK), 5 mg/ml lingham, Dorset, UK). The plates were read at 405 nm
following the addition of substrate (Sigma). All incuba-in TBSTM. Following extensive washing with TBSTM,
the strips were incubated for three hours at room temp- tions were 100 ml/well at 378C for one hour, with three
washes with PBS between stages. Antigen-free wellserature with a goat polyclonal anticeruloplasmin anti-
body (Biodesign International, Kennebunk, ME, USA), were included as controls, and the effect of the addition
of monoclonal and rabbit polyclonal antibodies (Dako)mouse monoclonal anti-MPO antibody (Dako, Glostrup,
Denmark), or human affinity-purified anti-MPO anti- was also studied.
body, so that each antibody was incubated with one strip
Measurement of myeloperoxidase activitythat had been preincubated with ceruloplasmin and one
that had not. An appropriate alkaline phosphatase- The assay used to determine MPO enzymatic peroxi-
conjugated antibody was then used to detect binding. dase activity was a modification of a standard method
by Andrews and Krinsky [15]. The colorless substrate
Enzyme-linked immunosorbent assays tetramethylbenzidine (Sigma) was oxidized by MPO in
the presence of hydrogen peroxide from colorless toMyeloperoxidase and the other cationic neutrophil en-
zymes—lactoferrin, proteinase 3, and bactericidal/per- blue. The reaction was stopped by the addition of acidic
sodium acetate buffer, and the extent of oxidation wasmeability-increasing protein (which acted as control vas-
culitis-associated autoantigens)—were each coated on a assessed by measuring the optical density at 620 nm.
Preincubation of MPO with ceruloplasmin or albuminmicrotiter ELISA plate. Ceruloplasmin in PBS with 1%
gelatin and 0.1% Tween20 was added at increasing con- at room temperature prior to performing the assay was
carried out to determine dose and time effects on MPOcentrations. The specificity of the binding to MPO was
confirmed by preincubation of ceruloplasmin with the activity. The activity was also measured for MPO alone
and in the presence of ceruloplasmin, affinity-purifiedcationic neutrophil enzymes prior to the addition to the
MPO-coated plate. The effect of anti-MPO antibodies anti-MPO antibodies, or both. Again, the effect of the
addition of monoclonal and rabbit polyclonal antibodieson the binding of ceruloplasmin was determined by the
addition of the affinity-purified antibodies to the MPO- (Dako) was also determined.
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Affinity constant measurement was eluted together with a small amount of IgG with
reactivity to MPO when assayed in an ELISA.The measurement of the affinity of the interaction
The binding between MPO and ceruloplasmin wasbetween MPO and ceruloplasmin and MPO and anti-
confirmed by Western blot (Fig. 2A), suggesting that theMPO antibodies was carried out using a biosensor (Bia-
interaction was not solely nonspecific and charge related,core BIALite, Stevenage, UK), with the results con-
although the relative pI values of 11.1 and 4.4, respec-firmed by chaotrope ELISA using ammonium thiocya-
tively, will favor binding under physiological conditions.nate [16]. The biosensor detects alterations in the angle
ELISA studies demonstrated concentration-dependentof minimal light reflectance to measure the accumulation
binding of ceruloplasmin to MPO, but not the otherof soluble molecules on the surface of a sensor chip to
cationic neutrophil enzymes (Fig. 2B), and this could bewhich their ligand is covalently bound. Direct calculation
competitively inhibited by MPO only (Fig. 2C).of association (ka) and dissociation (kd) rate constants is
Ceruloplasmin will inhibit to a maximum approachingpossible from the resulting graph of material bound
70% the peroxidase activity of MPO in both a concentra-against time, with the functional affinity (KA) expressed
tion- and time-dependent manner (Fig. 3), suggestingas the ratio between these calculations [17].
enzymatic inhibition rather than scavenging of the sub-CM5 research-grade chips were used throughout.
strate. Albumin had no effect on MPO activity (resultsThese were activated by amine coupling according to
not shown).the manufacturer’s instructions (Biacore, Stevenage,
UK) and were coupled with a rabbit polyclonal anti- Effect of anti-MPO antibodies on the interaction
MPO antibody (Dako). Affinity measurements were car- between MPO and ceruloplasmin
ried out using a running buffer of PBS at a flow rate of
The results of the effect of the addition of affinity-5 ml/min. Fifteen microliters of 50 mg/ml MPO was bound
purified antibodies on the interaction between MPO andto the initial capturing layer, and dissociation was al-
ceruloplasmin in ELISA, the ceruloplasmin-mediated in-lowed to proceed until a plateau was reached. The kd of hibition of MPO activity, and the apparent affinity ofthis interaction was of the order of 1025 s21 and, there-
their interaction with MPO are shown in Table 1. Thefore, did not affect the kinetic measurements of the sub-
maximal inhibition of binding of ceruloplasmin to MPO
sequently added ceruloplasmin or antibody. The affinity
by the monoclonal anti-MPO antibody was only 4.5 6
of the interaction between MPO and ceruloplasmin was
6.6% (N 5 4), but 95.8 6 1.0% (N 5 4) by the rabbit
measured 10 times over a concentration range of 1.5 to polyclonal anti-MPO antibody.
3.8 mm. The affinity of the interaction between MPO The anti-MPO antibodies could be divided into two
and nine of the antibody preparations was measured a groups when considering their effect on the interaction
median number of five times over a concentration range between MPO and ceruloplasmin: (a) those from pa-
of 42 to 667 nm. Regeneration to the capturing layer was tients with microscopic polyangiitis and florid renal vas-
with 10 mm HCl. culitis, and (b) those from patients with Wegener’s gran-
ulomatosis. The antibodies derived from the one patient
with Churg Strauss syndrome behaved in a similar man-RESULTS
ner to those from patients with microscopic polyangiitis.Interaction between myeloperoxidase
The microscopic polyangiitis group inhibited binding be-and ceruloplasmin
tween MPO and ceruloplasmin in an ELISA to a maxi-
The binding of ceruloplasmin to MPO was initially mum of 72.9 6 12.8% and reversed the ceruloplasmin-
identified when serum from a patient with anti-MPO mediated inhibition of MPO activity to a maximum of
antibody-associated vasculitis was passed over an MPO 77.6 6 19.5% (Fig. 4 A, B). In contrast, those from
column in order to affinity purify anti-MPO antibodies. patients with Wegener’s granulomatosis inhibited the
A gel of the eluted proteins revealed a band at approxi- ELISA binding to a maximum of 36.8 6 10.9% and
mately 130 kDa in addition to that expected for IgG reversed the ceruloplasmin-mediated inhibition to a
(Fig. 1A). The proteins eluted from the MPO column maximum of 20.3 6 14.7%. Three out of 15 samples in
were then run over a protein G column, with the unidenti- the microscopic polyangiitis group and two out of six
fied protein remaining in the unbound fraction (Fig. 1B). samples in the Wegener’s granulomatosis group inhib-
This was immunoblotted onto a polyvinyl difluoride ited MPO activity alone by 17 to 43%, and no reversal
(PVDF) membrane for sequencing of the 10 N-terminal of ceruloplasmin-mediated inhibition could be assessed.
amino acids, which showed 100% homology with human The presence of pooled IgG had no effect on the results
ceruloplasmin. In contrast to the results of Segelmark et of either assay. The two sets of results are highly corre-
al [8], no band corresponding to the complement compo- lated (Fig. 4C), suggesting that the displacement of ceru-
nent C3d was seen. Serum from 12 normal blood donors loplasmin binding by the antibodies is responsible for the
reversal of inhibition. Both the monoclonal and rabbitwas also passed over the columns, and ceruloplasmin
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Fig. 1. (A) Twelve percent polyacrylamide
gel of proteins eluted from myeloperoxidase
(MPO) column. Lane 1, molecular weight
markers (Amersham, Rainham, Essex, UK);
lane 2, eluted fraction, reduced in 5% 2 mer-
captoethanol and boiled for five minutes (IgG
heavy and light chains, ceruloplasmin); lane
3, eluted fraction, nonreduced (IgG and ceru-
loplasmin). (B) Twelve percent polyacryl-
amide gel of unbound and eluted proteins
from protein G column. Lane 1, molecular
weight markers; lane 2, eluted fraction re-
duced in 5% 2 mercaptoethanol and boiled
for five minutes (IgG heavy and light chains);
lane 3, unbound fraction, reduced (ceruloplas-
min); lane 4, eluted fraction, nonreduced
(IgG); lane 5, unbound fraction, nonreduced
(ceruloplasmin).
polyclonal anti-MPO antibodies themselves inhibited However, the affinity ranking was confirmed by ammo-
MPO activity, the monoclonal to a maximum of 91.0 6 nium thiocyanate disruption ELISA (results not shown).
6.5% (N 5 4), the polyclonal to a maximum of 81.8 6
6.6% (N 5 4).
DISCUSSIONThe mean affinity of the interaction between MPO
These studies provide evidence for a specific interac-and ceruloplasmin as measured in a biosensor was
tion between MPO and ceruloplasmin that results in the7.46 6 3.09 3 106 m21, which is lower than that between
inhibition of MPO enzymatic activity. They also describeMPO and the anti-MPO antibodies in both patient
a novel role for anti-MPO antibodies in reversing thisgroups (1.61 to 13.30 3 107 m21). This difference was
inhibition. Little has previously been understood of thesignificant for a majority of the antibodies (statistical
mechanisms of control of MPO activity in vivo, althoughanalysis by Welch’s alternate t-test), and these results
it has been suggested that this may occur by MPO inacti-are displayed in Table 1. Although well validated for the
vation by auto-oxidation by hypochlorous acid [19]. Spe-measurement of affinity using monoclonal antibodies,
cific enzymes exist to protect against intracellular oxygenthe biosensor is less robust when measuring the affinity of
radicals, namely catalase, superoxide dismutase, and glu-a polyclonal system [18]. The presence of heterogenous
tathione reductase, all of which metabolize reactive mol-affinities within a polyclonal antibody preparation makes
ecules once they are formed. The inhibition of MPO bythe reliable determination of both ka and kd difficult,
ceruloplasmin provides a mechanism for preventing theirand the variability in measured affinity for an individual
preparation in this study was higher than anticipated. initial generation. Although the circulating levels of
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Fig. 2. (A) Western blot of nonreduced myeloperoxidase (MPO) transferred to nitrocellulose. Lane 1, molecular weight markers; lanes 2 to 4,
no incubation with ceruloplasmin; lanes 5 to 7, overnight incubation with ceruloplasmin; lanes 2 and 5, 1 polyclonal anticeruloplasmin antibody;
lanes 3 and 6, 1 monoclonal anti-MPO antibody; lanes 4 and 7, 1 human affinity purified anti-MPO antibody. (B) The binding of ceruloplasmin
to cationic neutrophil enzymes. Symbols are: (j) proteinase 3; (m) lactoferrin; (h) bactericidal/permeability-increasing protein; (r) MPO. (C)
Effect of preincubation of ceruloplasmin with cationic neutrophil antigens on binding to MPO ([ceruloplasmin] 5 1 mg/ml). Symbols are: (m)
proteinase 3; (h) cathepsin G; (j) MPO.
Fig. 3. (A) Inhibition of MPO activity by ceruloplasmin: Concentration dependency. Results shown as mean 6 standard deviation of triplicates
for a representative experiment ([MPO] 5 10 mg/ml). The abbreviation is TMB, tetramethylbenzidine. (B) The inhibition of MPO activity by
ceruloplasmin: time dependency. Results shown as mean 6 standard deviation of triplicates for a representative experiment ([MPO] 5 5 mg/ml;
[ceruloplasmin] 5 100 mg/ml).
MPO are low, higher local concentrations may develop and aromatic amino acids, and it initiates reactions to
break peptide bonds [1]. The rapid reaction with nitrogenat sites of inflammation, and control by a plasma inhibitor
seems likely. This has already been described for neutro- compounds results in the formation of chloramines, more
stable oxidants that are likely to mediate the effects ofphil proteinases and a1AT [20].
The product of MPO activity, hypochlorous acid, oxi- MPO in vivo. MPO activity also leads to the generation
of the hydroxyl radical, which may result in both localdizes cofactors such as hem-groups and sulfur-containing
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Fig. 4. (A) Inhibition of ceruloplasmin binding to MPO by anti-MPO
antibodies (mean 6 standard deviation). Symbols in panels A and B
are: (n) IgG; (h) Wegener’s granulomatosis; (e) microscopic polyangi-
itis; *P , 0.05; **P , 0.01; ***P , 0.001. (B) Reversal of ceruloplasmin-
mediated inhibition of MPO oxidative activity (mean 6 standard devia-
tion). (C) Correlation between inhibition of binding in ELISA and
reversal of ceruloplasmin-mediated inhibition of MPO activity (r 5
0.8855, P , 0.0001, Spearman’s rank correlation coefficient).
cell damage and the initiation of a free-radical cascade- ide- and ferritin-dependent lipid peroxidation via the
mediating oxidative injury at more distant sites [21]. In ability to reincorporate reductively mobilized iron to
particular, lipid peroxidation of cell membrane polyun- ferritin [29]. This antioxidant potential has been sug-
saturated fatty acids results in a self-perpetuating, radi- gested as a critical function during the inflammatory
cally mediated reaction and has been implicated as a acute-phase response when levels may increase twofold
mechanism of cellular damage in atherosclerosis. The to threefold above baseline. This increased synthesis is
inhibition of MPO has been proposed to account for primarily hepatic; however, increased mRNA expression
the anti-inflammatory properties of several agents, in- has also been detected in the acutely inflamed lung of
cluding nonsteroidal anti-inflammatory drugs [22], meth- adult rats following endotoxin injection [30]. This local
ylxanthines such as theophylline [23], and propylthioura- production of ceruloplasmin may be important in the
cil [24]. limitation of neutrophil-mediated lung injury. In a group
Ceruloplasmin is a blue copper oxidase that oxidizes
of patients with the adult respiratory distress syndrome,
ferrous to ferric ions with the reduction of molecular
ceruloplasmin levels were increased as part of an acute-oxygen to water. The reactive ferrous ions are therefore
phase response; however, the plasma ferroxidase activityunavailable to catalyze the decomposition of hydrogen
was similar to a group of normal controls [31]. Thisperoxide to produce the hydroxyl radical (modified Ha-
suggests a relative loss of ceruloplasmin activity, possiblyber-Weiss or Fenton reaction) [25]. Thus, ceruloplasmin
increasing the susceptibility of these patients to oxidant-may be considered an antioxidant in that the reaction it
mediated tissue damage. A separate study has reportedcatalyzes does not result in the production of reactive
the presence of increased ceruloplasmin levels in theoxygen radicals. The antioxidant properties of cerulo-
bronchoalveolar lavage fluid from patients with the adultplasmin have been characterized by several groups [26–
respiratory distress syndrome and that this fluid was able28]. A nonspecific free-radical scavenging ability has
been described, in addition to the inhibition of superox- to protectively inhibit lipid peroxidation, as assessed by
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decreased formation of malondialdehyde in rat brain There is a precedent for this mode of action in the more
typical form of Wegener’s granulomatosis, which is usu-homogenate [32].
The structure of the active site of ceruloplasmin was ally associated with autoantibodies to another neutrophil
granule enzyme, proteinase 3. Although these autoanti-first suggested on the basis of anion-binding properties
and redox behavior and was later confirmed by crystallo- bodies have been reported to interfere with the complex-
ation between proteinase 3 and the physiological inhibi-graphic studies [33]. The presence of a novel trinuclear
configuration provides an oxygen binding and reduction tor a1AT, the autoantibodies themselves have also been
shown to inhibit proteinase 3 activity, and the mannersite. Crystallographic studies have also characterized the
structure of MPO [34], and the critical residues at the by which any in vivo effect on proteolytic activity is
brought about remains uncertain [39].active site have been determined by site-directed muta-
genesis [35]. Further information concerning the nature The presence of anti-MPO antibodies might be impor-
tant in the pathogenesis of renal vasculitis by their abilityof the active site has been obtained by cocrystallization
of MPO with an inhibitor, salicylhydroxamic acid, which to protect MPO from inactivation, resulting in the persis-
tent generation of reactive oxygen radicals in vivo, withbinds to the distal heme-pocket [36]. Our studies are
currently directed toward investigating the structural ba- enhanced potential for endothelial cytotoxicity. The dif-
ferent behavior of the antibodies derived from patientssis of the interaction between MPO and ceruloplasmin.
Anti-MPO antibodies from patients with renal vasculi- with microscopic polyangiitis and Wegener’s granuloma-
tosis suggests that different autoantibody epitope speci-tis reversed the ceruloplasmin-mediated inhibition of
MPO activity. In contrast, anti-MPO antibodies from ficity may influence disease manifestation.
patients with Wegener’s granulomatosis produced a
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